Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Daiichi Sankyo And Merck's Raludotatug Deruxtecan Shows 50.5% Objective Response Rate In Recurrent Platinum-Resistant Ovarian, Primary Peritoneal Or Fallopian Tube Cancer

Author: Benzinga Newsdesk | October 20, 2025 02:20am

An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the phase 2 part of REJOICE-Ovarian01
Phase 3 part of REJOICE-Ovarian01 to evaluate 5.6 mg/kg dose of raludotatug deruxtecan versus investigator's choice of chemotherapy

Posted In: DSNKY MRK